Although no distinct immune profile has been consistently linked to the clinical benefit in this cancer vaccine trial, we observed a possible link between the response, irPR and irSD, and the level of IFN-γ in the peripheral blood one day after each BVAC-C administration (Figure 3C). The gene discussed is IFNG; the disease is cancer.